OXiGENE, Inc., a biopharmaceutical company, engages in the development of novel small-molecule therapeutics to treat cancer and eye diseases. The company focuses on the development and commercialization of drug candidates that disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. It develops vascular disrupting agents (VDAs) and ortho-quinone prodrugs (OQPs). It develops VDAs for indications in oncology and ophthalmology; and OQPs for indications in oncology. The company?s products are in various clinical and preclinical trials for oncology and ophthalmology, as a single-agent and in combination with other therapies, including chemotherapy, radiotherapy, antibody therapy, and anti-vascular endothelial growth factor therapy. The company has collaborations with a various university and research institutions, including Gray Cancer Institute, Middlesex, the United Kingdom; Baylor University, Waco, Texas; Arizona State University, Tempe, Arizona; The University of Texas MD Anderson Cancer Center, Houston, Texas; and Beth Israel Deaconess Medical Center, Boston, Massachusetts. The company was incorporated in 1988 and is headquartered in Waltham, Massachusetts.